tetano
Editor, Senior Moderator
Am J Perinatol
. 2022 Aug 16.
doi: 10.1055/a-1925-2017. Online ahead of print.
Casirivimab and Imdevimab for Pregnant Women Hospitalized for Severe Coronavirus Disease 2019 (COVID-19)
Antonio Riccardo Buonomo[SUP] 1 [/SUP], Gabriele Saccone[SUP] 1 [/SUP], Nunzia Esposito[SUP] 1 [/SUP], Isabella Di Filippo[SUP] 1 [/SUP], Biagio Pinchera[SUP] 1 [/SUP], Maria Foggia[SUP] 1 [/SUP], Emanuela Zappulo[SUP] 1 [/SUP], Agnese Giaccone[SUP] 1 [/SUP], Nicola Schiano Moriello[SUP] 1 [/SUP], Giulio Viceconte[SUP] 1 [/SUP], Riccardo Scotto[SUP] 1 [/SUP], Giuseppe Bifulco[SUP] 1 [/SUP], Ivan Gentile[SUP] 1 [/SUP]
Affiliations
Abstract
Objective: To evaluate safety and efficacy of casirivimab/imdevimab therapy in pregnant women with severe COVID-19 requiring oxygen therapy.
Methods: This was a prospective case series study aimed to evaluate safety and efficacy of casirivimab/imdevimab therapy in unvaccinated pregnant women with severe COVID-19. Inclusion criteria were: SARS CoV-2 infection documented with PCR, pregnancy, severe COVID-19 requiring oxygen therapy, duration of symptoms of 10 days or less, able to provide informed consent. Vaccinated women, and those with mild-to-moderate disease were excluded from the study. Included patients received casirivimab and imdevimab as single intravenous dose of 4000/4000 mg. Women were also treated with low molecular weight heparin, steroids and antibiotics, if necessary. The primary outcome was maternal death. Secondary outcomes were: rate of adverse events during infusion or within 72 hours, and rate of abortion.
Results: Thirteen hospitalized unvaccinated pregnant women with severe COVID-19 requiring oxygen and treated with casirivimab/imdevimab were included in the study. We observed no maternal death, and no patients required intubation or admission to intensive care unit. No abortion or fetal loss were recorded. Nine pregnancies were still ongoing, and there were three cesarean deliveries and one vaginal delivery. Two were preterm deliveries (at 31 and 34 weeks), and two were term deliveries.
Conclusion: Casirivimab/imdevimab therapy may be considered as therapy in unvaccinated pregnant women with severe COVID-19.
. 2022 Aug 16.
doi: 10.1055/a-1925-2017. Online ahead of print.
Casirivimab and Imdevimab for Pregnant Women Hospitalized for Severe Coronavirus Disease 2019 (COVID-19)
Antonio Riccardo Buonomo[SUP] 1 [/SUP], Gabriele Saccone[SUP] 1 [/SUP], Nunzia Esposito[SUP] 1 [/SUP], Isabella Di Filippo[SUP] 1 [/SUP], Biagio Pinchera[SUP] 1 [/SUP], Maria Foggia[SUP] 1 [/SUP], Emanuela Zappulo[SUP] 1 [/SUP], Agnese Giaccone[SUP] 1 [/SUP], Nicola Schiano Moriello[SUP] 1 [/SUP], Giulio Viceconte[SUP] 1 [/SUP], Riccardo Scotto[SUP] 1 [/SUP], Giuseppe Bifulco[SUP] 1 [/SUP], Ivan Gentile[SUP] 1 [/SUP]
Affiliations
- PMID: 35973799
- DOI: 10.1055/a-1925-2017
Abstract
Objective: To evaluate safety and efficacy of casirivimab/imdevimab therapy in pregnant women with severe COVID-19 requiring oxygen therapy.
Methods: This was a prospective case series study aimed to evaluate safety and efficacy of casirivimab/imdevimab therapy in unvaccinated pregnant women with severe COVID-19. Inclusion criteria were: SARS CoV-2 infection documented with PCR, pregnancy, severe COVID-19 requiring oxygen therapy, duration of symptoms of 10 days or less, able to provide informed consent. Vaccinated women, and those with mild-to-moderate disease were excluded from the study. Included patients received casirivimab and imdevimab as single intravenous dose of 4000/4000 mg. Women were also treated with low molecular weight heparin, steroids and antibiotics, if necessary. The primary outcome was maternal death. Secondary outcomes were: rate of adverse events during infusion or within 72 hours, and rate of abortion.
Results: Thirteen hospitalized unvaccinated pregnant women with severe COVID-19 requiring oxygen and treated with casirivimab/imdevimab were included in the study. We observed no maternal death, and no patients required intubation or admission to intensive care unit. No abortion or fetal loss were recorded. Nine pregnancies were still ongoing, and there were three cesarean deliveries and one vaginal delivery. Two were preterm deliveries (at 31 and 34 weeks), and two were term deliveries.
Conclusion: Casirivimab/imdevimab therapy may be considered as therapy in unvaccinated pregnant women with severe COVID-19.